Journal
Molecular Genetics and Metabolism Reports
Publication Date
9-1-2021
Volume
28
First Page
100772
Document Type
Open Access Publication
DOI
10.1016/j.ymgmr.2021.100772
Rights and Permissions
Reynolds M, Linneman LA, Luna S, Warner BB, Turmelle YP, Kulkarni SS, Jiang X, Khanna G, Shinawi M, Porter FD, Ory DS, Cole FS, Dickson PI. A phase 1/2 open label nonrandomized clinical trial of intravenous 2-hydroxypropyl-β-cyclodextrin for acute liver disease in infants with Niemann-Pick C1. Mol Genet Metab Rep. 2021 May 26;28:100772. doi: 10.1016/j.ymgmr.2021.100772 © 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
Reynolds, Margaret; Linneman, Laura A; Luna, Sofia; Warner, Barbara B; Turmelle, Yumirle P; Kulkarni, Sakil S; Jiang, Xuntian; Khanna, Geetika; Shinawi, Marwan; Porter, Forbes D; Ory, Daniel S; Cole, F. Sessions; and Dickson, Patricia I, "A phase 1/2 open label nonrandomized clinical trial of intravenous 2-hydroxypropyl-β-cyclodextrin for acute liver disease in infants with Niemann-Pick C1." Molecular Genetics and Metabolism Reports. 28, 100772 (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10713
Supplementary Tables 1-4
